Phacilitate

  • About Us
    • Advisory Board
  • Insights and Resources
        • All Insights and Resources
          The latest and greatest Insights Phacilitate has to offer, across all our key sectors and mediums

        • Webinar Library
          View upcoming and past webinars about world of advanced therapies

           

          The Phacilitate Podcast
          Insightful conversations with industry leaders

        • Content Services
          We create game-changing content that empowers the advanced therapies industry

          • Industry Insights
            • Clinical Trials
            • Collaborations, Mergers and Acquisitions
            • Finance and Investment
            • GMP
            • Patient Access and Engagement
            • Regulatory and Standards
            • Reimbursement
            • Strategy
          • Manufacturing
            • Automation and Digitisation
            • Characterisation
            • CMC
            • GMP
            • Logistics
            • Partnering
            • Point of Care
            • Raw Materials
            • Scaling Up
            • Skills, Talent and Development
            • Supply Chain
          • Techniques
            • Allogeneic
            • Autologous
            • CAR-X
            • Cell Therapy
            • Gene Editing
            • Gene Therapy
            • NKx
            • Stem Cells
            • Viral/Non-viral Vectors
  • Latest News
  • Events
  • The Directory
    • The Cell and Gene Directory
    • Manufacturing Capacity Map
  • Membership
    • Phacilitate Network
    • Women in Advanced Therapies
Back
  • About Us
    • Advisory Board
  • Insights and Resources
        • All Insights and Resources
          The latest and greatest Insights Phacilitate has to offer, across all our key sectors and mediums

        • Webinar Library
          View upcoming and past webinars about world of advanced therapies

           

          The Phacilitate Podcast
          Insightful conversations with industry leaders

        • Content Services
          We create game-changing content that empowers the advanced therapies industry

          • Industry Insights
            • Clinical Trials
            • Collaborations, Mergers and Acquisitions
            • Finance and Investment
            • GMP
            • Patient Access and Engagement
            • Regulatory and Standards
            • Reimbursement
            • Strategy
          • Manufacturing
            • Automation and Digitisation
            • Characterisation
            • CMC
            • GMP
            • Logistics
            • Partnering
            • Point of Care
            • Raw Materials
            • Scaling Up
            • Skills, Talent and Development
            • Supply Chain
          • Techniques
            • Allogeneic
            • Autologous
            • CAR-X
            • Cell Therapy
            • Gene Editing
            • Gene Therapy
            • NKx
            • Stem Cells
            • Viral/Non-viral Vectors
  • Latest News
  • Events
  • The Directory
    • The Cell and Gene Directory
    • Manufacturing Capacity Map
  • Membership
    • Phacilitate Network
    • Women in Advanced Therapies
Join Today
Sign In
Sign In
Join Today

More results...

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
page
acf-ui-options-page
omapi
acf-taxonomy
acf-post-type
pha_member
lgx_lsp_shortcodes
speaker
e-book

Inceptor Bio and Avectas Collaborate to Improve Manufacturing of CAR-T’s for Solid Tumors

Banner
Ayaan Lowry
Anna Osborne
13 October 2022
SHARE NOW
CAR-X
Cell Therapy
Collaborations, Mergers & Acquisitions
Cell therapy biotechnology company Inceptor Bio and Engineering technology leader Avectas, announce they will collaborate to improve the manufacturing and development of next-generation CAR-T cell therapies for solid tumors.

This successful collaboration will utilize Avectas’ breakthrough cell engineering technology, SOLUPORE®, and Inceptor Bio’s novel CAR-T platform.

Avectas’ SOLUPORE® allows companies to overcome the current delivery modalities’ limitations in cell engineering, including complex cell engineering, by integrating into the product manufacturing processes.

The non-viral SOLUPORE ® technology enables molecular cargo to be delivered into cells efficiently, whilst maintaining high cell functionality and viability levels, by permeabilizing the target cell membrane.

“Avectas is delighted to collaborate with Inceptor Bio to leverage the benefits of the SOLUPORE delivery platform for solid tumor CAR-T cell therapies. Excellent cell health and functionality, after complex editing, are critical to the success of these next-generation therapies,” commented Michael Maguire, Avectas CEO.

How are you enjoying this news article? Let us know your thoughts, here >>

Under the collaboration agreement, Inceptor will use SOLUPORE® technology as an alternative to electroporation when engineering T cells, in order to produce a healthier T cell product.

This technology will complement and enhance Inceptor’s CAR-T cell process. It will enable the development of engineered T cells that have better durability in the tumor microenvironment. This will improve the CAR-T therapeutic performance and efficiency in the treatment of solid tumors.

Avectas’ SOLUPORE® is well matched to Inceptors Bio’s CAR-T cell process. In the long run they aim to enhance their durability in the microenvironment of the tumor.

“Inceptor Bio is committed to building and advancing a pipeline of programs based on diversified cell therapies, including CAR-M, CAR-T, and CAR-NK. This collaboration with Avectas is part of our strategy of advancing Inceptor Bio’s next-generation cell therapy platform focused on multiple novel mechanisms to address solid tumors,” said Shailesh Maingi, Founder and CEO of Inceptor Bio.

Source: Avectas Press Release


While we have you…

We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.

More like this

20 Years of Advanced Therapies with David McCall: a Retrospective on Phacilitate’s Founding and Evolution of the Industry

Lee Buckler, SVP Advanced Therapies, Blood Centers of America, Advanced Therapies Network, reflects on two decades of working within the advanced therapies industry as Phacilitate celebrates 20 years of operating in the field.
4 December 2023

Oxford Biomedica Acquires ABL Europe from Institut Mérieux

Oxford Biomedica Acquires ABL Europe from Institut Mérieux
6 December 2023

Texas Children’s Hospital First to Deliver a Novel Gene Therapy for Rett Syndrome

Two female pediatric patients with Rett syndrome were the first children worldwide to receive the promising treatment with Neurogene’s lead gene therapy product.
5 December 2023

Discover more like this

20 Years of Advanced Therapies with David McCall: a Retrospective on Phacilitate’s Founding and Evolution of the Industry

Oxford Biomedica Acquires ABL Europe from Institut Mérieux

Texas Children’s Hospital First to Deliver a Novel Gene Therapy for Rett Syndrome

FDA Investigating ‘Serious Risk’ of Secondary Malignancy Linked to BCMA- or CD19-Directed CAR-T Immunotherapies

Sernova’s Hemophilia A Program Receives Orphan Drug and Rare Pediatric Disease Designations from FDA

logo_footer
logo_mobile_footer
Company
  • About Us
  • Events
  • Contact Us
Resources
  • Insights and Resources
  • Latest News
  • Phacilitate Podcast
  • Content Services
Network
  • Sign In
  • Join Today
social_icon Linkedin
social_icon Twitter

Clarion Events Limited is registered in England and Wales, Company Number 00454826, VAT No. GB 843845601 Registered Office: Bedford House, 69-79 Fulham High Street, London, SW6 3JW, United Kingdom.

  • Privacy Policy
  • Code of Conduct
  • Terms & Conditions
  • Cookies
Phacilitate is a part of Clarion Events Limited. © Phacilitate 2022